Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma
Abstract To identify risk factors for infection in patients with diffuse large B cell lymphoma (DLBCL) undergoing rituximab, cyclophosphamide, vincristine, adriamycin and prednisolone (R-CHOP) treatment. All patients with DLBCL who received R-CHOP from 2004–2014 in a tertiary Australian hospital wer...
Guardado en:
Autores principales: | Claire Dendle, Michael Gilbertson, Tim Spelman, Rhonda L. Stuart, Tony M. Korman, Karin Thursky, Stephen Opat, Zoe McQuilten |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a6a1943b81149ab8bde5882ee1cadd6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma
por: Kirsten Thobe, et al.
Publicado: (2021) -
Immune targeted therapy for diffuse large B cell lymphoma
por: Yaxin Zheng, et al.
Publicado: (2021) -
TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Ebru Pekgüç, et al.
Publicado: (2021) -
Epstein-Barr Virus-Positive Adrenal Diffuse Large B-Cell Lymphoma after Treatment for Angioimmunoblastic T-Cell Lymphoma
por: Akiko Hashimoto, et al.
Publicado: (2021) -
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
por: Jiang Xiao, et al.
Publicado: (2017)